TOP2A and ovarian cancer: Furthermore, none of them have been validated in ovarian cancer, which makes it impossible to clarify the role of TOP2A in cisplatin resistance of ovarian cancer (31, 32), suggesting functional crosstalk between the two pathways.However, in OC, direct evidence is still lacking regarding whether targeting a single key factor can simultaneously activate ferroptosis and block EMT, thereby reversing cisplatin resistance.More importantly, whether TOP2A is involved in the aforementioned crosstalk constitutes a critical gap in the current research field.